STOCK TITAN
  1. Home
  2. News
  3. LEGN

Legend Biotech Corporation American Depositary Shares - LEGN STOCK NEWS

Welcome to our dedicated page for Legend Biotech Corporation American Depositary Shares news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech Corporation American Depositary Shares stock.

Legend Biotech Corporation (Symbol: LEGN) is an emerging clinical-stage biopharmaceutical company dedicated to the development and commercialization of cutting-edge immunotherapy technology aimed at curing cancer. The company leverages its expertise in immunology and molecular biology to advance a robust pipeline of chimeric antigen receptor (CAR) product candidates designed to address a variety of liquid and solid tumors.

Legend Biotech's primary focus is on developing CAR-T cell therapies, which have shown great promise in clinical trials. One of their flagship products, LCAR-B38M/JNJ-4528, targets multiple myeloma, a previously incurable blood cancer. Recent clinical trial results have demonstrated significant success in treating patients with refractory and relapsed multiple myeloma, showcasing the potential of their proprietary CAR-T technology.

Founded with a vision to revolutionize cancer treatment, Legend Biotech aims to safely and effectively treat previously untreatable cancers with finely-tuned CAR-T products developed through their innovative technology platform. The company's ambition has been notably fulfilled by their advances in the CARs field, as evidenced by their promising clinical outcomes.

Legend Biotech collaborates extensively with leading immunologists and molecular biologists to enhance their research and development efforts. They generate significant revenue from license and collaboration agreements, primarily from the United States.

Stay updated with the latest news and developments regarding Legend Biotech Corporation on this dedicated page.

News

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

Rhea-AI Summary
Legend Biotech's CARVYKTI® receives FDA approval for treating relapsed or refractory multiple myeloma, offering a new treatment option with improved progression-free survival. The therapy targets B-cell Maturation Antigen, providing hope for patients and physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
-
News

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) releases its inaugural Environmental, Social & Governance (ESG) report, showcasing commitment to patients, employees, and communities. Key pillars include patient care, innovation, employee engagement, community involvement, operational efficiency, and integrity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none
-
News

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Rhea-AI Summary
Legend Biotech's CARVYKTI Receives Positive FDA ODAC Vote for Multiple Myeloma Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
News

Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights

Rhea-AI Summary
Legend Biotech (LEGN) reports net trade sales of $159 million for Q4 2023 and $500 million for the full year. FDA to review data for CARVYKTI® label expansion. Legend received $100 million upfront payment from Novartis. Financially, they have $1.3 billion in cash and equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
earnings
-
News

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

Rhea-AI Summary
Legend Biotech's CARVYKTI® receives positive CHMP opinion for expanded label in treating relapsed and refractory multiple myeloma patients, supported by CARTITUDE-4 study results. The therapy aims to provide innovative treatment options to patients in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.1%
Tags
none
-
News

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

Rhea-AI Summary
Legend Biotech Corporation (LEGN) will host a conference call to review fourth-quarter and full-year 2023 results. Executive members will discuss the company's performance during the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
conferences earnings
News

Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

Rhea-AI Summary
Legend Biotech Corporation (LEGN) has closed an exclusive worldwide license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend Biotech’s existing autologous CAR-T cell therapy candidate, LB2102 (NCT05680922). Under the terms of the agreement, Legend Biotech will receive a $100 million upfront cash payment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
-
News

Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) will participate in the 42nd annual J.P. Morgan Healthcare Conference. Ying Huang, Ph.D., the company’s CEO, will deliver the presentation on Tuesday, January 9, 2024, at 2:15 p.m. PT. The live audio webcast will be available on Legend’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
conferences
-
News

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) announced that patient-reported outcome (PRO) data from the Phase 3 CARTITUDE-4 study showed clinically meaningful improvement in health-related quality of life following a single CARVYKTI® infusion in adults lenalidomide-refractory multiple myeloma (MM) patients. The as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall response. Longer-term data from CARTITUDE-2 showed deep and durable responses in earlier lines of treatment among patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
News

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) reported unaudited financial results for the three and nine months ended September 30, 2023. The company entered into an exclusive, global license agreement with Novartis Pharma AG for potential chimeric antigen receptor T-cell (CAR-T) therapies targeting Delta-like ligand 3 (DLL3). Novartis will pay an upfront payment of $100 million and up to $1.01 billion in milestone payments. CARVYKTI® generated approximately $152 million in net trade sales during the quarter, representing a 30% increase over the previous quarter. The company also received milestone payments and appointed a new General Counsel. Legend Biotech has $1.4 billion in cash and cash equivalents, deposits, and short-term investments as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
earnings

FAQ

What is the current stock price of Legend Biotech Corporation American Depositary Shares (LEGN)?

The current stock price of Legend Biotech Corporation American Depositary Shares (LEGN) is $40.94 as of November 22, 2024.

What is the market cap of Legend Biotech Corporation American Depositary Shares (LEGN)?

The market cap of Legend Biotech Corporation American Depositary Shares (LEGN) is approximately 7.4B.

What is Legend Biotech Corporation's main focus?

Legend Biotech focuses on developing and commercializing immunotherapy technology to treat various types of cancer.

What is CAR-T therapy?

CAR-T therapy involves modifying T cells to express chimeric antigen receptors that can target and destroy cancer cells.

What is Legend Biotech's lead product candidate?

Their lead product candidate is LCAR-B38M/JNJ-4528, a CAR-T cell therapy for treating multiple myeloma.

What types of cancer does Legend Biotech target?

Legend Biotech targets a wide range of liquid and solid tumors, with a significant focus on multiple myeloma.

Where does Legend Biotech generate most of its revenue?

The majority of Legend Biotech's revenue comes from the United States through license and collaboration agreements.

How successful have Legend Biotech's clinical trials been?

Their clinical trials have shown promising results, particularly in treating patients with refractory and relapsed multiple myeloma.

Who are Legend Biotech's collaborators?

Legend Biotech collaborates with leading immunologists and molecular biologists to advance their research and development.

What is the vision behind Legend Biotech's founding?

The company was founded on the vision of safely and effectively treating previously incurable cancers with innovative technology.

What is unique about Legend Biotech's technology platform?

Their platform focuses on developing finely-tuned CAR-T products, which have demonstrated significant clinical success.

How can I stay updated on Legend Biotech's latest news?

You can stay updated by following the latest news and developments on their dedicated page on StockTitan.

Stock LEGN logo
Legend Biotech Corporation American Depositary Shares

Nasdaq:LEGN

LEGN Rankings

#1051 Ranked by Market Cap
N/A Ranked by Dividends

LEGN Stock Data

7.41B
181.05M
1.31%
51.22%
8.61%
Biotechnology
Healthcare
Link
United States of America
Somerset